Akebia Therapeutics (AKBA) Leases: 2019-2025
Historic Leases for Akebia Therapeutics (AKBA) over the last 7 years, with Sep 2025 value amounting to $4.8 million.
- Akebia Therapeutics' Leases fell 47.99% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year decrease of 47.99%. This contributed to the annual value of $8.2 million for FY2024, which is 33.81% down from last year.
- Latest data reveals that Akebia Therapeutics reported Leases of $4.8 million as of Q3 2025, which was down 19.21% from $6.0 million recorded in Q2 2025.
- Over the past 5 years, Akebia Therapeutics' Leases peaked at $33.9 million during Q4 2021, and registered a low of $4.8 million during Q3 2025.
- Its 3-year average for Leases is $11.4 million, with a median of $10.4 million in 2024.
- In the last 5 years, Akebia Therapeutics' Leases spiked by 30.81% in 2022 and then tumbled by 59.23% in 2024.
- Over the past 5 years, Akebia Therapeutics' Leases (Quarterly) stood at $33.9 million in 2021, then declined by 13.87% to $29.2 million in 2022, then crashed by 57.42% to $12.4 million in 2023, then slumped by 33.81% to $8.2 million in 2024, then plummeted by 47.99% to $4.8 million in 2025.
- Its Leases was $4.8 million in Q3 2025, compared to $6.0 million in Q2 2025 and $7.1 million in Q1 2025.